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Hypertension is a progressive cardiovascular disease that arises from many differing but inter-related etiologies \[[@CR1]\]. Early markers of the syndrome are often present before there is a sustained rise in blood pressure (BP) elevation. Hypertension therefore, cannot be classified solely using discrete BP parameters \[[@CR1], [@CR2]\]. Progression of the syndrome is strongly associated with functional and structural cardiac and vascular abnormalities that damage the heart, kidneys, brain, vasculature, and other organs, which in turn leads to premature morbidity and death \[[@CR1]\]. Hypertension is the most prevalent cardiovascular (CV) disorder in developed countries and affects 20% to 50% of the adult population \[[@CR2]\].

The European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines \[[@CR3]\] and the World Health Organization--International Society of Hypertension (WHO/ISH) guidelines \[[@CR4]\] suggested that BP control can be described as adequate when systolic and diastolic BPs of \< 140 mm Hg and \< 90 mm Hg, respectively, are achieved.

Furthermore the Joint National Committee (JNC) 7 and European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines \[[@CR3], [@CR5]\] have suggested that systolic and diastolic BP values of \< 130 mm Hg and \< 80 mm Hg, respectively, should be the target range for special populations such as those affected by diabetes or renal disease. However, the current recommendations of the ESH (2009) indicate that we do not have enough data to demonstrate that a decreased in BP below 130/80 mm Hg is connected with the reduction of cardiovascular events. Moreover, intensive BP lowering might increase CV events (the J-curve phenomenon) \[[@CR6]•\].

Epidemiologic data have revealed that the BP control is achieved in only a small percentage of hypertensive patients \[[@CR6]•, [@CR7], [@CR8]\]. In central European countries, BP control is only 20% to 25%.

Many studies have demonstrated that elevated BP is a risk factor for coronary heart disease, heart failure, stroke, peripheral arterial disease, and renal failure in both men and women (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR9]--[@CR13]\]. Fig. 1Elevated blood pressure is a risk factor for many cardiovascular diseases. *CAD* coronary artery disease, *CHF* congestive heart failure, *LVH* left ventricular hypertrophy, *PVD* peripheral vascular disease

There is evidence that raised BP inversely correlates with cognitive function and that hypertension is associated with an increased incidence of dementia \[[@CR14]\]. Data from studies involving 1 million patients have indicated that death from both CHD and stroke increases progressively and linearly from BP levels as low as 115 mm Hg systolic and 75 mm Hg diastolic \[[@CR15]\]. Increased risks are present in all age groups, ranging from 40 to 89 years old. For every 20-mm Hg systolic or 10-mm Hg diastolic increase in BP, there is a doubling of mortality from both CHD and stroke. In addition, longitudinal data obtained from the Framingham Heart Study have indicated that BP values in the 130--139/85--89 mm Hg range are associated with a more than twofold increase in relative risk from cardiovascular disease compared with those with BP levels below 120/80 mm Hg \[[@CR16]\].

A large number of randomized trials have confirmed that the main benefits of antihypertensive therapy are the result of BP lowering per se, independent of the class of drug used to lower blood pressure \[[@CR17]\].

The odds ratio or the relative risk of CVD to the individual increases with the severity of hypertension, although the attributable risk is greatest for mild hypertension due to its greater prevalence in the general population. Therefore, the burden of CVD arising from hypertension in the general population comes from those with relatively mild BP elevation \[[@CR18]\].

Compared to normotensive individuals, those with an elevated BP have an increased tendency to have other risk factors for CVD (ie, diabetes, insulin resistance, dyslipidemia) \[[@CR19], [@CR20]\], together with various types and degrees of target organ damage. Because risk factors may interact positively with each other, the total CV risk of hypertensive patients is frequently high when BP elevation is only mild or moderate \[[@CR21]\].

The Prevalence and Awareness of Hypertension {#Sec2}
============================================

When comparing the prevalence of hypertension, one should be aware that this is heavily dependent on the definition of hypertension, the nature of the population being studied, the number of BP readings taken on each occasion and, finally, on the number of visits to the doctor \[[@CR22]•\]. The prevalence of hypertension reported by Kearney et al. \[[@CR23]\] varies widely, with rates as low as 3.4% in rural Indian men and as high as 72.5% in Polish women. Subregions with populations where consistently high mean systolic BP levels have been detected include parts of Eastern Europe and Africa. A comparative analysis of hypertension in North Americans aged 35 to 64 years showed a 60% lower prevalence of hypertension compared to similar subjects in European countries \[[@CR23]\]. The difference in prevalence could not be explained by differences in body mass index (North America 27.1 kg/m^2^, Europe 26.9 kg/m^2^). Findings from the WHO project Monitoring Trends and Determinants in Cardiovascular Diseases (MONICA) Project showed a remarkably higher prevalence of hypertension in Eastern Europe (about 65%), but virtually no difference in the rates of controlled hypertension among Eastern and Western populations \[[@CR24], [@CR25]\]. Epidemiologic studies (NATPOL III Plus) indicate that the prevalence of hypertension in Polish population is 67%. Of all patients with hypertension in Poland, only 12% are successfully treated (Table [1](#Tab1){ref-type="table"}) \[[@CR26]\]. Table 1The effectiveness of diagnosis and treatment among adults Poles with hypertension in NATPOL III PLUSHypertensionWomenMenGenerallyNot detected27%40%33%Detected, not treated8%13%10%Treated unsuccessfully51%37%45%Treated successfully14%10%12%(*Adapted from* Zdrojewski et al. \[[@CR26]\])

The data from the Polish multicenter, nationwide project WOBASZ assessed 13,545 subjects (6392 men and 7153 women) in the years 2003 to 2005 and showed that the average incidence of hypertension in Poland was about 36% \[[@CR27]\]. Hypertension was more commonly detected in men (42.1%) compared to women (32.9%). This sex difference did depend, however, on the age at which the hypertension was detected \[[@CR27]\]. The percentage of patients with controlled BP was low (10% in men and 16% in women). This confirms the observations from the NATPOL III study, where BP control in the overall population of treated hypertensive patients was only 12% \[[@CR26]\].

In Russia, 97.1% of the hypertensive population was above the recommended target level (\<140/90 mm Hg) at their first visit to an outpatient department. BP control was poorer in patients with a BP target of \< 130/80 mm Hg (20.1%) than in those with a higher target BP (25.9%) \[[@CR28]\].

Detecting hypertension depends on both the awareness of population and the intervention of medical staff and should be aimed at the recording of elevated BP, even in symptomless patients. In the Czech Republic, there was an increase in the awareness of the dangers of hypertension (from 49.5% to 67.2%) and the treatment of hypertension (from 29.3% to 49.3%) from 1985 to 2001 \[[@CR29]\]. Regional differences in BP levels have been observed in a number of developed countries. Differences were reported between urban and rural populations, with a tendency toward higher BP levels in urban areas.

What Influences Compliance with Antihypertensive Therapy in Eastern Europe? {#Sec3}
===========================================================================

The compliance of medical staff in following antihypertension treatment guidelines is variable. A study conducted on a random sample of Polish primary care doctors working in clinics contracted by the National Health Insurance Funds aimed to assess whether the doctors were following particular drug regimen guidelines. Doctors completed a questionnaire consisting of eight case vignettes describing patients with elevated BP \[[@CR30]•\]. The cases differed on three variables related to the level of blood pressure, the presence or absence of diabetes mellitus, and the presence or absence of other risk factors. Doctors were asked to give their treatment decision in each case. One hundred twenty-five doctors (65% response rate) completed the questionnaire. Compliance with treatment guidelines was judged to be 51%. Poor compliance with guidelines was noted for patients with diabetes mellitus. The level of blood pressure was the strongest predictor of drug treatment. Angiotensin-converting enzyme (ACE) inhibitors were the most frequently prescribed medications. Appropriate decisions were more commonly associated with medical practices in large cities \[[@CR30]•\].

Insufficient use of diuretics in combination antihypertensive therapy is a main cause of poor BP control in Russia. The objective of the Russian ARGUS-2 \[[@CR31]•\] study was to demonstrate that a rational use of a thiazide-like diuretic, indapamide sustained release (SR), alone or in combination, improved BP control in patients with difficult-to-control hypertension. The open-label, non-comparative 3-month study without preliminary washout included 1438 hypertensive patients (mean age 57.3 ± 10.7 years, mean BP 158.8 ± 14.2/93.4 ± 10.0 mm Hg), with difficult-to-control arterial hypertension who had never been treated with diuretics. Throughout the study, patients received indapamide SR 1.5 mg daily. BP control was defined as \< 140/90 mm Hg for all patients and \< 130/80 mm Hg for those with diabetes mellitus or chronic nephropathy \[[@CR31]•\]. Approximately 75.7% of patients also were prescribed an ACE inhibitor or an angiotensin II receptors blocker, 43.9% a calcium channel blocker, and 32.8% a β-blocker. The study demonstrated the value of including the thiazide-like diuretic indapamide SR in a combined antihypertensive regimen to control BP in hypertensive patients with added cardiovascular risk factors whose hypertension is difficult to treat. In 3 months after indapamide SR administration, average BP level decreased to 131.8 ± 9.7/80.5 ± 6.9 mmHg, and 84.5% of the study population achieved BP control. BP was controlled in 91.9% of patients with isolated systolic hypertension (*n* = 477), 74.8% of those with diabetes (*n* = 214), 75.6% of those with chronic nephropathy (*n* = 82), and 85.1% of patients with metabolic syndrome (*n* = 745) \[[@CR31]•\].

In Russia, achieving a BP target was associated with combination therapy, a higher rate of diuretic administration, and more frequent visits to the physician \[[@CR28]\]. During hospitalization, a target BP of \< 140/\< 90 mm Hg was achieved in 87.1% of patients, and \< 130/\< 80 mm Hg in 76.2% of patients. Low adherence to antihypertensive treatment, lack of patient knowledge about the risks related to hypertension, and financial problems were identified as the main barriers to improve control of BP. Patients considered financial issues related to antihypertensive treatment as being much less important compared to their physicians \[[@CR28]\].

Bajraktari et al. \[[@CR32]\] assessed the quality of the management of hypertension in patients hospitalized in the cardiology service in Kosovo. They studied patients who were mainly referred from general practitioners, internists, and cardiologists for a better treatment of hypertension or because hypertension was associated with other co-morbidities needing hospitalization. This retrospective study included 938 consecutive hypertensive patients (63.1 ± 11.3 years, 55.1% women). Angiotensin-converting enzyme inhibitors (ACEI) and/or angiotensin II receptor blockers were the drugs most commonly prescribed in their study group (83%). β-blockers (BB) were the second group of the drugs that were prescribed (71%), followed by diuretics (60%), and calcium channel blockers (26%). The most frequent drug combination used was ACEI, BB, and diuretic (30.5%). Adequate systolic and diastolic blood pressures were achieved in 50% of patients. Multivariate analysis identified diabetes, (odds ratio \[OR\] = 0.479; 95% CI, 0.339--0.677; *P* \< 0.001), creatinine level (OR = 0.997; 95% CI, 0.996--0.999; *P* = 0.001), and combination therapy (OR = 0.445; 95% CI, 0.253--0.774; *P* = 0.046) as independent correlates of in-hospital poor BP control \[[@CR32]\].

It has been demonstrated that the optimal BP control was far better during in-hospital treatment of hypertensive patients than in those treated in primary health care units \[[@CR32]--[@CR35]\]. Moreover, the behavior of physicians attending hypertensive patients (including careful examination and detailed information given on the rules of hypertension therapy and hypertension complications) was shown to be a factor that may influence better BP control in in-hospital hypertension units \[[@CR36], [@CR37]\].

Hypertension in the Elderly {#Sec4}
===========================

The management of hypertension in the elderly is a significant problem in the countries of Eastern Europe. Prevalence of hypertension increases with age, rising steeply after the age of 50 years, and affects more than 50% of this population. In adulthood, systolic and diastolic BP tends to rise with age. The increase is somewhat greater in systolic BP, whereas diastolic BP remains almost unaltered from age 50 years and upward. Aging results in a progressive increase in pulse pressure, which is the difference between systolic and diastolic pressure \[[@CR24], [@CR38]\].

Guidelines for the management of hypertension include areas where the evidence for or against treatment in certain types patient groups is inconclusive. This is especially the case of older patients with hypertension \[[@CR3], [@CR4]\].

Although a large number of randomized trials that have included hypertensive patients aged ≥ 60 years have shown that antihypertensive drugs reduce cardiovascular morbidity and mortality, health care professionals are often reluctant to prescribe adequate antihypertensive therapy \[[@CR39]\].

In a meta-analysis by the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC) \[[@CR40]\], the effects of different drugs in reducing BP in older and younger adults were analyzed. The reduction in BP and the relative risk reduction of a cardiovascular event with various antihypertensive drugs occurred independently of patient age. The benefits of the antihypertensive regimens were widely comparable across age groups independent of the drug class \[[@CR40]\]. The BPLTTC analysis strongly suggested that there should be early and aggressive management of hypertension irrespective of age \[[@CR40]\].

The Hypertension in the Very Elderly Trial (HYVET) \[[@CR41]\] was a double-blind, placebo-controlled trial that included 3845 patients aged \> 80 years who had sustained systolic BP ≥ 160 mm Hg or diastolic hypertension (90--109 mmHg). Patients were randomized to either SR indapamide 1.5 mg or placebo. In the first group, perindopril was added as needed. Results of the HYVET study proved that early and systematic therapy of hypertension with indapamide or indapamide and perindopril in this age group reduces the risk of all-cause mortality (21%), fatal and non-fatal stroke (30%), and mortality and heart failure (64%) development. The treatment of hypertension demands comprehensive approach to the patient regarding global cardiovascular risk and individualization of hypertensive therapy \[[@CR41]\]. These studies were very important as they confirmed that we should treat hypertension irrespective of age, but we still do not know what should be the target BP in elderly patients. However, it is worth noting that on the basis of data from HYVET, in which the systolic BP was actually lowered to 143 mm Hg, American recommendations suggest lowering the systolic BP in persons aged 80 years and older to 140 to 145 mm Hg if tolerated. This is important data for Eastern Europeans countries, because there is no current standard for optimal therapy of elderly patients \[[@CR41]--[@CR44]\].

What is the best drug to treat hypertension in older and younger adults? There are a few pathophysiologic mechanisms that are specific in the elderly. This includes the age-related increase in postsynaptic α-adrenoceptor--mediated and calcium influx--dependent vasoconstriction, as well as a decrease in plasma renin activity. The recently revised British guidelines \[[@CR42]\] suggested that patients younger than 55 years should be treated with ACE inhibitors and older patients with diuretics or calcium channel blockers. On the other hand, other European guidelines \[[@CR3], [@CR4]\] suggest that evidence for an age-dependent strategy in the choice of antihypertensive drugs is as yet insufficient. In fact, benefits have been demonstrated in older hypertensive patients for several drug classes such as diuretics, calcium channel blockers, ACE inhibitors, angiotensin receptor blockers (ARB), and BBs \[[@CR43]--[@CR46]\].

The first drug of choice in older patients often needs to be precisely tailored to individual characteristics, as older adults frequently have other risk factors, target organ damage, and other associated clinical conditions. Additionally, many patients will need two or more drugs to control BP, since in the very old it can be particularly difficult to obtain a systolic BP of lower than 140 mmHg \[[@CR39], [@CR47], [@CR48]\].

Conclusions {#Sec5}
===========

Despite continuously accumulating data, many decisions on hypertension management must still be taken without the support of evidence from available clinical trials. The problem with the optimal control and treatment of hypertension is especially important for Central and Eastern European countries, given the high prevalence of hypertension, but the reasons of the problems are the same as in Western European countries and the United States. These reasons, and obviously the problems of compliance and therapeutic inertia are the most important reasons that hypertension remains the most important risk factor for cardiovascular disease and the greatest contributor to mortality worldwide \[[@CR49]•, [@CR50]•, [@CR51]--[@CR55]\].
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